Evidence map›Paper›PMID 41704766›Full record

ArticleiScience2026

Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment.

Vito W Rebecca, Min Xiao, Andrew Kossenkov, Tetiana Godok, Gregory Schuyler Brown, Dylan Fingerman, Gretchen M Alicea, Meihan Wei, Hongkai Ji, Marie Portuallo and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Vito W RebeccaThe Wistar Institute, Philadelphia, PA, USA.
Min XiaoThe Wistar Institute, Philadelphia, PA, USA.
Andrew KossenkovThe Wistar Institute, Philadelphia, PA, USA.
Tetiana GodokThe Wistar Institute, Philadelphia, PA, USA.
Gregory Schuyler BrownThe Wistar Institute, Philadelphia, PA, USA.
Dylan FingermanThe Wistar Institute, Philadelphia, PA, USA.
Gretchen M AliceaThe Wistar Institute, Philadelphia, PA, USA.
Meihan WeiJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Hongkai JiJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Marie PortualloJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jeremy BravoJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Vissy EladJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Yeqing ChenThe Wistar Institute, Philadelphia, PA, USA.
Eneda ToskaJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mitchell E FaneThe Wistar Institute, Philadelphia, PA, USA.
Kasey L CoutsUniversity of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.
Jessie VillanuevaThe Wistar Institute, Philadelphia, PA, USA.
Katherine NathansonUniversity of Pennsylvania, Philadelphia, PA, USA.
Keerthana M ArunDepartment of Cell and Developmental Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Govind WarrierDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xiangfan YinThe Wistar Institute, Philadelphia, PA, USA.
Jianyi DingThe Wistar Institute, Philadelphia, PA, USA.
Qin LiuThe Wistar Institute, Philadelphia, PA, USA.
Yogesh GoyalUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y N Vashisht GopalUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA.

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
NCI NIH HHS P30 CA010815
6 · The paper itself

Abstract

Although BRAF/MEK inhibitor (BRAFi/MEKi) therapy initially shows high efficacy in patients with

Indexed as

CancerTherapeutics

Identifiers

PMID41704766
PMCPMC12907876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.